Brazil's expanded newborn screening program has reached only three states five years after legislation authorized the broader diagnostic panel [3].
This failure to implement the expanded tests nationwide leaves thousands of newborns without early detection for rare diseases. Timely diagnosis is critical for initiating treatments that prevent severe disability or death in infants.
The National Newborn Screening Program, known as "teste do pezinho," has operated for 25 years [1]. The standard procedure involves collecting a blood-spot sample from a newborn's heel between 48 hours and five days after birth [2]. This window is essential to ensure the accuracy of the screening for various conditions [2].
To improve health outcomes, Brazil passed Federal Law No. 14.154/2021 [5]. This law was intended to expand the number of conditions screened, moving beyond the basic panel to include a wider array of rare diseases [3]. However, five years after the law's passage, the rollout remains limited [3].
Currently, only three Brazilian states have adopted the expanded version of the test [4]. The disparity in implementation means that a child's access to life-saving early detection depends on their state of birth, a gap that contradicts the national intent of the 2021 legislation [3].
The program aims to enable early detection of rare diseases and other serious conditions [3]. By identifying these issues shortly after birth, healthcare providers can implement interventions that significantly improve the long-term health, and survival rates, of affected newborns [3].
“Only three states have implemented the expanded blood-spot test designed to detect rare diseases in infants.”
The gap between the passage of Federal Law No. 14.154/2021 and its actual implementation highlights a systemic failure in translating national health policy into local practice. Because newborn screening is a time-sensitive intervention, the lack of a uniform national rollout creates a geographic lottery for infant healthcare, where the quality of preventative medicine is determined by state-level administration rather than federal mandate.
